Table 1.
All subjects (n=128) | ||
---|---|---|
Characteristic | Mean ± SD | n (%) |
Age (years) | 50 ± 14 | |
Sex | ||
Female | 95 (74) | |
Race/Ethnicity | ||
White, non-Hispanic | 80 (63) | |
Black | 9 (7) | |
Hispanic | 19 (15) | |
Asian | 14 (11) | |
Other | 6 (5) | |
Etiology of pulmonary hypertension | ||
Idiopathic pulmonary arterial hypertension | 50 (39) | |
Associated pulmonary arterial hypertension | ||
Connective tissue diseases | 36 (28) | |
Congenital heart diseases | 3 (2) | |
Portal hypertension | 16 (13) | |
HIV infection | 6 (5) | |
Drug- and toxin-induced | 11 (9) | |
Other | 6 (5) | |
Right heart catheterization data | ||
Mean right atrial pressure (mmHg)* | 11 ± 8 | |
Mean pulmonary artery pressure (mmHg) | 50 ± 13 | |
Mean pulmonary capillary wedge pressure (mmHg) | 9.8 ± 4.0 | |
Cardiac index (L/min·m2)* | 2.4 ± 0.9 | |
Pulmonary vascular resistance (dyne·sec·cm−5)* | 886 ± 464 | |
WHO functional class | ||
Class I | 8 (6) | |
Class II | 45 (35) | |
Class III | 66 (52) | |
Class IV | 9 (7) | |
6-minute walk test† | ||
6-minute walk distance (m) | 348 ± 115 | |
Borg dyspnea index, post-walk | 2.7 ± 2.0 | |
Medications | ||
Intravenous or subcutaneous prostacyclin infusion | 49 (38) | |
Inhaled prostacyclin | 4 (3) | |
Oral endothelin receptor antagonist | 82 (64) | |
Oral phosphodiesterase-5 inhibitor | 41 (32) |
WHO: World Health Organization
Missing for 7 subjects
Missing for 3 subjects